Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
NCT01105429 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2011-03-09
Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug, as well as the amount of study drug in the blood, in subjects with type 2 diabetes.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
Interventions
- DRUG
-
BMS-820132
Oral Solution, Oral, 0.3 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral, 1.0 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral, 3 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral, 10 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral, 30 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral , 75 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral, 150 mg, once daily, 1 day
- DRUG
-
BMS-820132
Oral Solution, Oral, 300 mg, once daily, 1 day
- DRUG
-
BMS-820132
Capsule, Oral, (TBD), once daily, 2 days
- DRUG
-
Oral Solution, Oral, 0mg, once daily, 1 day
- DRUG
-
Capsule, Oral, (TBD), once daily, 2 days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2010-10-31
- Completion
- 2010-10-31
Countries
- United States
Study Locations
More Related Trials
-
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
NCT00458016 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
NCT01956305 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus
NCT00836940 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
NCT01640873 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
NCT00263276 ·Status: COMPLETED ·Phase: PHASE2
-
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
NCT01017302 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
NCT05158244 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
NCT05731544 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
NCT01129258 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
NCT01358929 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
NCT00995787 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
NCT05478525 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
NCT00478322 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527 ·Status: COMPLETED ·Phase: PHASE3
-
Multiple Ascending Dose Study in Subjects With Type 2 Diabetes
NCT01856881 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
NCT00972322 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
NCT00856908 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
NCT02004678 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
NCT02211261 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
NCT01396187 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
NCT00513214 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Single Ascending Dose Trial in Patients With Type 2 Diabetes
NCT01492465 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes
NCT02212925 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes
NCT01282970 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
NCT01217073 ·Status: COMPLETED ·Phase: PHASE2